No More Generics? Implications Of The US Pricing Bill

Lilly’s view of the impact of the pending US drug pricing reform legislation is that it will require rethinking of all its small molecule development programs. That may sound extreme, but it is a logical response to the incentives in the bill. Does that mean the end of the generic drug era?

Generic drugs
Will industry pivot away from small molecule drugs in the wake of new drug pricing legislation? • Source: Shutterstock

The pharmaceutical industry appears to be fighting a losing battle against comprehensive pricing legislation in the US, so it may be easy to ignore the eleventh-hour warnings about the potential impact of the bill.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

More from Pink Sheet